Table 5.
Genotypic distribution of SNPs in CETP gene and associated with risk for type 2 diabetes (T2D) patients with diabetic kidney disease (DKD) and diabetic retinopathy (DR).
| dbSNP ID/Effect Allele 1 | Genotype/Effect Allele Number | T2D Patients with DKD/without DKD N = 367/958 |
T2D with DKD vs. without DKD OR (95% CI), p-Value |
T2D Patients With DR/ Non-DR N = 475/588 |
DR vs. Non-DR OR (95% CI), p-Value |
|---|---|---|---|---|---|
| rs3764261/A | CC/0 | 235 (74.4)/650 (70.0) | 0.78 (0.58–1.04), 0.094 2 | 335 (70.5)/406 (69.2) | 0.90 (0.70–1.16), 0.408 2 |
| AC/1 | 74 (23.4)/254 (27.4) | 0.80 (0.60–1.08), 0.154 3 | 133 (28.0)/169 (28.8) | 0.90 (0.70–1.16), 0.414 3 | |
| AA/2 | 7 (2.2)/24 (2.6) | 7 (1.5)/12 (2.0) | |||
| rs4783961/A | GG/0 | 207 (65.5)/574 (61.9) | 0.82 (0.63–1.06), 0.126 2 | 295 (62.1)/360 (61.2) | 0.90 (0.72–1.12), 0.341 2 |
| AG/1 | 97 (30.7)/310 (33.4) | 0.84 (0.65–1.09), 0.186 3 | 164 (34.5)/202 (34.4) | 0.89 (0.71–1.12), 0.318 3 | |
| AA/2 | 12 (3.8)/44 (4.7) | 16 (3.4)/26 (4.4) | |||
| rs1800775/A | CC/0 | 85 (26.9)/221 (23.8) | 0.78 (0.64–0.96), 0.019 2 | 104 (21.9)/142 (24.1) | 0.98 (0.82–1.17), 0.816 2 |
| AC/1 | 169 (53.5)/456 (49.1) | 0.80 (0.65–0.98), 0.032 3 | 251 (53.0)/290 (49.3) | 0.98 (0.82–1.17), 0.810 3 | |
| AA/2 | 62 (19.6)/252 (27.1) | 119 (25.1)/156 (26.5) | |||
| rs5882/G | AA/0 | 105 (33.4)/270 (29.2) | 0.83 (0.68–1.02), 0.083 2 | 144 (30.4)/175 (29.9) | 0.94 (0.79–1.13), 0.506 2 |
| AG/1 | 155 (49.4)/458 (49.5) | 0.83 (0.67–1.03), 0.086 3 | 237 (50.0)/277 (47.4) | 0.94 (0.79–1.13), 0.506 3 | |
| GG/2 | 54 (17.2)/197 (21.3) | 93 (19.6)/133 (22.7) |
dbSNP ID, SNP database identification; T2D, type 2 diabetes; DKD, diabetic kidney disease; DR, diabetic retinopathy; OR, odds ratio; CI, confidence interval; 1 Effect allele is defined as the allele associated with higher HDL-cholesterol; 2 Adjusted for age, sex, and HbA1C; 3 Adjusted for age, sex, HbA1C, and BMI.